OneOncology | Strategic Alliance Partnership

The centers for research are named for Anthony Greco, MD, and John Hainsworth, MD, who founded Sarah Cannon in 1993 as Tennessee Oncology physician researchers.

Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.

“OneOncology was started by physicians and for physicians,” said Jeff Patton, MD, OneOncology CEO. “As we’ve grown and enhanced world-class cancer care in communities across the country, strengthening practice independence and empowering their decision-making has always been our north star."

Use of SignalPath will improve efficiency, ease compliance, boost enrollment, and ensure financial success in clinical trials, leaders said in interviews.

Jeff Patton, MD, CEO of OneOncology, joins Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for episode 3 of "Oncology Onward: Conversations With Innovators and Changemakers in Cancer Care."

Coverage of research presented by Strategic Alliance Partners: OneOncology, Florida Cancer Specialists & Research Institute, and The US Oncology Network.

Tennessee Oncology collaborated with Smirta to develop the platform.

The Enhancing Oncology Model (EOM) attracted more than 2800 practitioners across 561 sites of care; a group of practices in the American Oncology Network enrolled under a single tax ID number.

While the final number of EOM practices will be fewer than the numbers in the OCM, the presence of Tennessee Oncology, Texas Oncology, and Northwest Medical Specialties will ensure participation of key leaders who succeeded in the OCM and have weighed in on what's needed in its replacement.

Initiating targeted therapy for eligible patients with advanced non–small cell lung cancer (NSCLC) was found to improve outcomes, even when patients were started on nontargeted therapy but switched in a timely manner.

A study presented at the American Society of Clinical Oncology Annual Meeting found practice- and provider-level racial and ethnic inequities in rates of next-generation sequencing (NGS) testing for patients with advanced non–small cell lung cancer (NSCLC) treated in the community setting.

The session, “Payment Reform: Lessons Learned from the Oncology Care Model (OCM) and Implications for the Enhancing Oncology Model (EOM)," comes less than a month before the EOM is set to begin.

Thomas Stricker, MD, PhD, and Gregory Vidal, MD, PhD, are both first authors on their respective abstracts involving patients with advanced non-small cell lung cancer in the community setting.

The multisite practice receives a key designation from a major and announces it is formally taking over a proton therapy center where its radiation oncologists already serve patients.

Stephen M. Schleicher, MD, MBA, Tennessee Oncology, co-authored a recent paper on the complexities of the rural cancer experience; the principal conclusion was potential for a streamlined care process to optimize care efficiencies and access, thereby improving patient outcomes.

OneOncology now has partner practices in 14 states.

Under the transaction, TPG, an asset management firm, will acquire a majority interest in OneOncology and AmerisourceBergen will have a minority interest; OneOncology physician leaders and practices will retain minority interests as well.

Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.

The practice is OneOncology's 16th partners overall and its first in Florida.

Oncologists express concerns about the replacement for the Oncology Care Model; the EOM is set to start July 1, 2023.

Coming soon: the inaugural episode of "Oncology Onward: Conversations With Innovators and Changemakers in Cancer Care,” with hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA.

Biomarker testing is a key tool in lung cancer treatment, and Kentucky recently passed a law requiring payers to cover biomarker tests with the intention to address high rates of lung cancer in the state.

Davey B. Daniel, MD, chief medical officer at OneOncology, shares his insights on health equity practices, as well as the importance of developing clinical models within community oncology.

Stephen M. Schleicher, MD, MBA, chief medical officer at Tennessee Oncology, discusses the present state of value-based oncology care and what the future may bring when the Enhancing Oncology Model kicks off on July 1.